MedTrace Logo

Management of Retinitis Pigmentosa Via Electromagnetic Stimulation and Platelet Rich Plasma

NCT04252534 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-02-05

No results posted yet for this study

Summary

The aim of this study is to investigate whether natural progression rate can be slowed down with subtenon PRP or PRP application combined with rEMS in retinitis pigmentosa cases.

Conditions

Interventions

COMBINATION_PRODUCT

PRP combined Magnovision

The rEMS helmet is used to stimulate the retina and visual pathways. (MagnovisionTM) combined with subtenon platelet rich plasma injection

BIOLOGICAL

PRP

Fresh autologous platelet rich plasma, injected subtenon space.

Sponsors & Collaborators

  • Ankara Universitesi Teknokent

    lead OTHER

Principal Investigators

  • Umut Arslan, MD · Ankara Universitesi Teknokent

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2019-12-30
Completion
2019-12-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04252534 on ClinicalTrials.gov